Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance thalidomide after first-line pemetrexed-based chemotherapy for malignant mesothelioma
NL-OMON24002Phase 3Active, not recruiting
- Sponsor
- NVALT
- Start
- Sep 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of thalidomide in mesothelioma, sponsored by NVALT. Started Sep 2004; status: active, not recruiting.
02
Drugs
thalidomide
03
Conditions
mesothelioma
Beyond the preview
Go deeper on NL-OMON24002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON24002.